Date: 2018-03-15
Type of information: Series B financing round
Company: Ideaya Bioscience (USA - CA)
Investors: BVF Partners (USA - CA) Perceptive Advisors (USA - NY) 6 Dimensions Capital (China) Tavistock Group (Bahamas) Nextech Invest (Switzerland) GV (USA - CA) Roche Venture Fund (Switzerland) 5AM Ventures (USA - CA) Canaan Partners (USA - CA) Celgene (USA - NJ) WuXi Healthcare Ventures (China) Novartis Institute of Biomedical Research -Alexandria Real Estate
Amount: $94 million
Funding type: series B financing round
Planned used:
- Synthetic lethality has become a therapeutic reality with the regulatory approval of PARP inhibitors in BRCA-deficient cancers. Ideaya is pioneering the next generation of biomarker-enabled synthetic lethality therapies for genetically defined patient populations and advancing an immuno-oncology pipeline targeting immuno-metabolism and innate immunity. Utilizing proceeds from the financing, Ideaya will advance its pipeline with a goal of initiating multiple clinical studies in 2019.
Others:
- • On March 15, 2018, Ideaya Biosciences, an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies, announced the successful completion of a $94 million crossover Series B financing. New investors, including BVF Partners , Perceptive Advisors Nextech Invest, GV (formerly Google Ventures), Roche Venture Fund, 6 Dimensions Capital, Boxer Capital of the Tavistock Group, and Driehaus Capital Management, joined existing investors, including 5AM Ventures, Canaan Partners, Celgene Corporation, WuXi Healthcare Ventures, and Alexandria Venture Investments, in the financing.
- Coincident with the close of the Series B financing, Thilo Schroeder, partner at Nextech Invest, and Edward Hu, founding partner of 6 Dimensions Capital, joined the company’s board of directors. Kanishka Pothula, managing director at BVF Partners, Vineeta Agarwala, venture partner at GV, and Nisha Marathe, investment manager at Roche Venture Fund, joined as board observers.
Therapeutic area: Cancer - Oncology
Is general: Yes
